Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.51 |
| ▸ | CA3 | P07451 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204727 | 0.84 | ALOX15 (0.64) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11025532 | 0.83 | ALOX15 (0.51) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6954737 | 0.83 | ALOX15 (0.58) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4447451 | 0.83 | ALOX15 (0.51) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1685055 | 0.81 | HSD17B10 (0.61) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5032715 | 0.79 | FGFR1 (0.43) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18991593 | 0.79 | HSD17B10 (0.66) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11844044 | 0.79 | ALOX15 (0.55) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10318989 | 0.78 | CYP2D6 (0.40) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11845978 | 0.78 | ALOX15 (0.53) | ALOX15HSD17B10CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024128568-A1 | BENZIMIDAZOLYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 경북대학교 산학협력단 | 2024-06-20 | — | — | WO | claimed |
| US-20130317222-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL]-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-28 | — | — | US | claimed |
| EP-2663558-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL}-1H-BENZIMIDAZOL-2-YL]UREA | Vertex Pharmaceuticals Incorporated (US) | 2013-11-20 | — | — | EP | claimed |
| US-8481552-B2 | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | claimed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012097270-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL}-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | WO | claimed |
| US-8124359-B2 | Use of additives for the reduction of non-specific binding in assays | AOKIN AG (DE) | 2012-02-28 | — | — | US | claimed |
| US-7993855-B2 | Use of additives to lower the rate of a binding reaction | AOKIN AG (DE) | 2011-08-09 | — | — | US | claimed |
| US-20090317922-A1 | USE OF ADDITIVES TO LOWER THE RATE OF A BINDING REACTION | AOKIN AG (DE) | 2009-12-24 | — | — | US | claimed |
| US-20090311724-A1 | USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS | AOKIN AG (DE) | 2009-12-17 | — | — | US | claimed |
| EP-2005170-A1 | USE OF ADDITIVES TO LOWER THE RATE OF A BINDING REACTION | AOKIN AG (DE) | 2008-12-24 | — | — | EP | claimed |
| EP-2005169-A2 | USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS | AOKIN AG (DE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007111851-A1 | USE OF ADDITIVES TO LOWER THE RATE OF A BINDING REACTION | AOKIN AG (DE) | 2007-10-04 | — | — | WO | claimed |
| WO-2007111847-A2 | USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS | AOKIN AG (DE) | 2007-10-04 | — | — | WO | claimed |
| CN-120513231-A | Benzimidazolyl urea derivatives and pharmaceutical use thereof | 庆北大学校产学协力团 | 2025-08-19 | — | — | CN | disclosed |
| WO-2024128568-A1 | BENZIMIDAZOLYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 경북대학교 산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| US-11766419-B2 | Mebeverine as soluble epoxide hydrolase inhibitor | BANASTHALI VIDYAPITH (IN) | 2023-09-26 | — | — | US | disclosed |
| US-4088768-A | BENZIMIDAZOLYL, BENZOTHIAZOLYL, AND BENZOXAZOLYL UREAS AND THIOUREAS | ELI LILLY AND COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4053598-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
| US-3951920-A | Permselective polymeric membrane prepared from polybenzimidazoles | TEIJIN LIMITED (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317222-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL]-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | ALOX15 4530/4885HSD17B10 1953/4885CYP1A2 516/4885 |
| US-11766419-B2 | Mebeverine as soluble epoxide hydrolase inhibitor | EPHX1, EPHX2, NCEH1 | ALOX15 312/4885HSD17B10 104/4885CYP1A2 71/4885 |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | ALOX15 4594/4885HSD17B10 2134/4885CYP1A2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.